Kamal Hamed - Sep 13, 2023 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Signature
/s/ Tamara Joseph, Attorney-in-Fact for Kamal Hamed
Stock symbol
SPRO
Transactions as of
Sep 13, 2023
Transactions value $
-$50,160
Form type
4
Date filed
9/15/2023, 05:47 PM
Previous filing
Jun 14, 2023
Next filing
Feb 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRO Common Stock Sale -$50.2K -39.5K -6.41% $1.27 576K Sep 13, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of (i) restricted stock units ("RSUs") that were granted to the Reporting Person on September 12, 2022 pursuant to a "sell to cover" provision included in the RSU Agreement and (ii) performance-based restricted stock units ("PSUs") that were granted to the Reporting Person on August 4, 2022, subject to the achievement of certain pre-established performance criteria, which the Board of Directors of the Issuer determined had been 100% met on June 12, 2023, pursuant to a "sell to cover" provision included in the PSU Agreement.
F2 The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $1.27 to $1.295 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.